R&D channel feed

Pox­el pass­es 3rd straight Phase III di­a­betes tri­al in Japan, but what's go­ing on with US/EU part­ner Roivant?

6 years ago

On the heels of pock­et­ing $30M from Alex­ion, Stealth Bio says its PhI­II was a flop

6 years ago

Top 10 sur­pris­es for bio­phar­ma in 2020? Cowen's biotech team of­fers a few ideas to chew on

6 years ago

Jazz rolls the dice on a bil­lion-dol­lar gam­ble on a new drug for SCLC — shoot­ing for a 2020 launch

6 years ago

Take­da puts $120M in near-term cash on the ta­ble to com­plete a new on­col­o­gy plat­form deal

6 years ago

Seat­tle Ge­net­ics gets ready to launch its sec­ond ADC af­ter scor­ing blad­der can­cer OK with part­ner Astel­las

6 years ago
FDA+

Har­vard taps Tish­man Spey­er to man­age first phase of its new 36-acre re­search cam­pus — and biotechs can't wait

6 years ago

An­oth­er de­pres­sion tri­al goes bust, as Min­er­va drug fails PhII study

6 years ago

Tox is­sues? Check. Ques­tion­able ef­fi­ca­cy da­ta? Check. OK to mar­ket? ODAC says check that box for Epizyme

6 years ago

Af­ter be­ing re­peat­ed­ly jilt­ed, this biotech was swept off its feet in a race to ASH: In­side Mer­ck­'s $2.7B Ar­Qule buy­out

6 years ago

Oh Cana­da! There is no San­ta Claus to the north giv­ing out cheap drugs to US pa­tients

6 years ago
Bioregnum
Opinion

ARCH-backed biotech emerges with $85M and a bold claim: A new hu­man hor­mone can re­verse a key ef­fect of ag­ing

6 years ago

Psy­che­del­ic re­search gains mo­men­tum, as ear­ly tri­al sug­gests mi­cro-dos­ing LSD is safe

6 years ago

Af­ter tak­ing a hard look at the da­ta, No­var­tis punts Aduro’s STING drug — the lat­est in a long line of set­backs

6 years ago

Eli Lil­ly spot­lights ear­ly on­col­o­gy in first pipeline re­view since R&D shift

6 years ago

Ver­sus Ver­tex, Pro­teosta­sis' triplet CF da­ta fall short, wilt­ing stock

6 years ago

Bio­haven cel­e­brates PhII/III win for in­tranasal CGRP mi­graine drug amid oral race with Al­ler­gan

6 years ago

FDA’s in-house re­view of­fers bleak as­sess­ment of Epizyme’s tazeme­to­stat — but win or lose this can­cer drug may still have a fu­ture

6 years ago
FDA+

Seer rais­es $55M as pro­teomics ap­proach­es prime time in dis­ease de­tec­tion, drug de­vel­op­ment

6 years ago

Promis­es made, promis­es kept: Al­ny­lam CEO John Maraganore adds 3rd straight pos­i­tive piv­otal as he aims at an­oth­er new drug OK

6 years ago

In crowd­ed prostate can­cer mar­ket, Pfiz­er's Xtan­di notch­es third ap­proval for use in ear­li­er stage of dis­ease

6 years ago
FDA+

GSK poised to leap back in­to the on­col­o­gy mar­ket with more pos­i­tive be­lan­tam­ab mafodotin re­sults — but BC­MA ri­vals are swarm­ing in be­hind

6 years ago

FTC to Roche: OK, go ahead and com­plete your $4.3B Spark buy­out — we're con­vinced now this is­n't an­ti­com­pet­i­tive

6 years ago

Yet an­oth­er NASH de­feat for Gilead as 3-drug cock­tail fiz­zles. Now one an­a­lyst says it's time for a change-up

6 years ago
First page Previous page 217218219220221222223 Next page Last page
A service from the Financial Times